Financing will support the development of novel surfaceome-targeted therapies for hard-to-treat tumors ...

Bio Usawa Inc., a biotechnology company dedicated to developing and delivering high-quality, affordable medicines, today announced the appointment of Professor Prashant Yadav as Director and Chair of ...

Extensive clinical and real-world validation: Heartflow’s AI-driven solutions have been validated through clinical evidence in over 100 studies assessing over 365,000 patients. Proven in real-world ...

Evry, December 11th 2025 - Eukar s, a Paris-based biotechnology company developing the world’s first multifunctional RNA polymerase to boost biomanufacturing yields in mammalian cells, today announced ...

With improved patient benefit as the driving principle for all we do, ITM advances a broad precision oncology pipeline, including multiple phase 3 studies, combining the company’s high-quality ...

Accèdez sans limite aux 15 000 actualités du site et recevez gratuitement chaque semaine, la Newsletter Santé log avec les actus Santé à ne pas manquer !

This meeting is not an official program of the ASH Annual Meeting.

The Jianxing center in East China will be the first CGI center to install X-ray technology. It will provide expanded irradiation capacity to this medical device centralized area as well as abundant ...

Immunovant offered 26.2 million shares of its common stock in the offering at an offering price of $21.00 per share. The offering is expected to close on or about December 12, 2025, subject to ...

Zealand Pharma targets five launches, +10 clinical pipeline programs, and industry-leading cycle times from idea to clinic by 2030 Catalyst-rich 2026 with multiple clinical readouts, including Phase 2 ...

LR BV100 Phase 3 in Ventilator Associated Bacterial Pneumonia initiated with first country submission completed and first patients to be dosed in the coming months – Phase 3 read-out expected in H2 ...

Under the partnership, Phare Bio will deploy its Generative AI platform to design molecules with antibacterial properties that meet a pre-defined target product profile, which considers both unmet ...